| BCBS Highmark West Virginia | Ocrelizumab (Ocrevus) and Ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo) | 2026-09-01 |
| BCBS Highmark West Virginia | Rozanolixizumab-noli (Rystiggo) | 2026-09-01 |
| BCBS Highmark West Virginia | Pegloticase (Krystexxa) | 2026-09-01 |
| BCBS Highmark West Virginia | Complement Inhibitors | 2026-09-01 |
| BCBS Highmark West Virginia | Denosumab (Prolia, Xgeva) and Denosumab Biosimilars | 2026-09-01 |
| UHC UMR Medical and Drug | Clotting Factors, Coagulant Blood Products, & Other Hemostatics – Commercial Medical Benefit Drug Policy | 2026-09-01 |
| UHC Surest Medical and Drug | Clotting Factors, Coagulant Blood Products, & Other Hemostatics – Commercial Medical Benefit Drug Policy | 2026-09-01 |
| UHC Commercial Medical & Drug | Autologous Cellular Therapy – Commercial and Individual Exchange Medical Policy | 2026-09-01 |
| UHC Commercial Medical & Drug | Clinical Trials – Commercial and Individual Exchange Medical Policy | 2026-09-01 |
| UHC Commercial Medical & Drug | Clotting Factors, Coagulant Blood Products, & Other Hemostatics – Commercial Medical Benefit Drug Policy | 2026-09-01 |